The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows:

**ADVICE:** following a full submission considered under the orphan process

**cannabidiol (Epidyolex®)** is accepted for use within NHSScotland.

**Indication under review:** for use as adjunctive therapy of seizures associated with Dravet syndrome, in conjunction with clobazam, for patients 2 years of age and older.

In two phase III, placebo-controlled studies cannabidiol reduced convulsive seizure frequency in the clobazam-treated subgroup of children (aged 2 to 18 years) with Dravet syndrome that was inadequately controlled by other anti-epileptic drugs.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.

Chairman
Scottish Medicines Consortium
**Indication**
For use as adjunctive therapy of seizures associated with Dravet syndrome, in conjunction with clobazam, for patients 2 years of age and older.¹

**Dosing Information**
The recommended starting dose of cannabidiol is 2.5mg/kg taken twice daily (5mg/kg/day) for one week. After one week, the dose should be increased to a maintenance dose of 5mg/kg twice daily (10mg/kg/day). Based on individual clinical response and tolerability, each dose can be further increased in weekly increments of 2.5mg/kg administered twice daily (5mg/kg/day) up to a maximum recommended dose of 10mg/kg twice daily (20mg/kg/day).

Any dose increases above 10mg/kg/day, up to the maximum recommended dose of 20mg/kg/day, should be made considering individual benefit and risk and with adherence to the full monitoring schedule. If cannabidiol has to be discontinued, the dose should be decreased gradually. In clinical trials, cannabidiol discontinuation was achieved by reducing the dose by approximately 10% per day for 10 days. A slower or faster down titration may be required, as clinically indicated, at the discretion of the prescriber.

Food may increase cannabidiol levels and therefore it should be taken consistently either with or without food, including the ketogenic diet.

Cannabidiol should be initiated and supervised by physicians with experience in the treatment of epilepsy.¹

**Product availability date**
January 2020
Cannabidiol in this indication meets SMC orphan criteria.

**Summary of evidence on comparative efficacy**
Cannabidiol is an anti-epileptic drug (AED) with a mechanism of action that is in part due to a two-way pharmacokinetic interaction with clobazam, which increases by 3-fold the clobazam active metabolite (N-desmethylclobazam) and increases by 1.5 fold the cannabidiol active metabolite (7-hydroxy-cannabidiol). Cannabidiol may have additional effects, but these are not fully characterised and are not produced via cannabinoid receptors.¹

Two similar double-blind studies (CARE1 and CARE2) recruited patients aged 2 to 18 years with Dravet syndrome and seizures inadequately controlled (defined by at least four convulsive seizures during 28-day baseline) on stable dose(s) for at least four weeks of AED therapy. In both studies patients continued on stable doses of AED and randomisation was stratified by age (2 to 5, 6 to 12 or 13 to 18 years). In CARE1 patients were equally assigned to cannabidiol oral solution titrated to 20mg/kg/day divided into two doses or placebo for 14 weeks. In CARE2 patients were assigned in a 2:2:1:1 ratio to cannabidiol oral solution titrated to 20mg/kg/day or 10mg/kg/day divided into two doses or matching placebos for 14 weeks. The primary endpoint in both studies was change...
from baseline in 28-day convulsive seizure frequency during the 14-week treatment period expressed as a percentage of baseline frequency. These were assessed in the intention-to-treat (ITT) population which comprised all patients who received study drug and had post-baseline efficacy assessment.\textsuperscript{2,3}

The primary outcome in both studies indicated significantly greater reductions in 28-day convulsive seizure frequency with cannabidiol compared with placebo in the total ITT population and favoured cannabidiol in the clobazam-treated subgroup, which is representative of the licensed indication, as detailed in Table 1. Treatment effects in the total population were mainly driven by effects within the clobazam-treated subgroup. The European Medicines Agency (EMA) review noted that the magnitude of treatment effects in patients who were not receiving concomitant clobazam have not been shown to be statistically or clinically relevant.\textsuperscript{2}

Table 1: CARE1 and CARE2 primary outcome: percent change (reduction) from baseline in 28-day convulsive seizure frequency.\textsuperscript{1,2}

<table>
<thead>
<tr>
<th></th>
<th>Total ITT Study Population</th>
<th></th>
<th></th>
<th></th>
<th>Clobazam-Treated Subgroup</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Change*</td>
<td>Difference (95%CI)</td>
<td>N</td>
<td>Change*</td>
<td>Difference (95%CI)</td>
<td></td>
</tr>
<tr>
<td>CARE1 cannabidiol 20mg/kg/day</td>
<td>61</td>
<td>39%</td>
<td>23% (5.4% to 41%)</td>
<td>40</td>
<td>54%</td>
<td>43% (17% to 60%)</td>
<td></td>
</tr>
<tr>
<td>placebo</td>
<td>59</td>
<td>13%</td>
<td></td>
<td>38</td>
<td>19%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CARE2 cannabidiol 20mg/kg/day</td>
<td>67</td>
<td>46%</td>
<td>26% (2.9% to 43%)</td>
<td>40</td>
<td>57%</td>
<td>31% (3.6% to 50%)</td>
<td></td>
</tr>
<tr>
<td>cannabidiol 10mg/kg/day</td>
<td>66</td>
<td>49%</td>
<td>30% (8.4% to 46%)</td>
<td>45</td>
<td>61%</td>
<td>37% (14% to 54%)</td>
<td></td>
</tr>
<tr>
<td>placebo</td>
<td>65</td>
<td>27%</td>
<td></td>
<td>41</td>
<td>38%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CI = confidence interval; Difference = compared with placebo; * = difference in 28-day convulsive seizure frequency during 14-week treatment period compared with 28-day baseline period frequency expressed as a percentage of 28-day baseline frequency.

For the EU licence application secondary endpoints in CARE1 were tested hierarchically, starting with the key secondary outcome proportion of patients with ≥50% reduction in convulsive seizures, for which the difference between treatment groups was not significant. In CARE2 key secondary outcomes were tested in a hierarchical order starting with 20 mg/kg/day dose followed by 10 mg/kg/day dose within each in the following order: change in total seizure frequency, ≥50% reduction in convulsive seizures, then caregiver global impression of change (CGIC) at the last visit.

In CARE2 there were significant improvements in all secondary outcomes with both doses of cannabidiol, compared with placebo in the ITT population.\textsuperscript{1-4} Available data for secondary outcomes in the clobazam-treated subgroup, representative of the licensed indication, are detailed in Table 2. There were no data in this subgroup for CGIC. However, in the total population at the end of treatment CGIC was improved (slightly improved, much improved, or very much improved) for more patients in the cannabidiol group, compared with placebo, in CARE1: 62% versus 34%; and in CARE2 for more patients in the cannabidiol 20mg and 10mg groups, compared with placebo: 61% and 68% versus 42%.\textsuperscript{2,3}
Table 2: Secondary outcomes of CARE1 and CARE2 in clobazam-treated subgroup.²

<table>
<thead>
<tr>
<th></th>
<th>CARE1</th>
<th></th>
<th>CARE2</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>cannabidiol 20mg/kg/day</td>
<td>Placebo</td>
<td>cannabidiol 20mg/kg/day</td>
</tr>
<tr>
<td>N</td>
<td>40</td>
<td>38</td>
<td>40</td>
<td>45</td>
</tr>
<tr>
<td>≥50% reduction in convulsive seizure frequency</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Responders</td>
<td>48%</td>
<td>24%</td>
<td>62%</td>
<td>56%</td>
</tr>
<tr>
<td>OR (95% CI)</td>
<td>2.9 (1.1; 7.8)</td>
<td>3.3 (1.3; 8.3)</td>
<td>2.3 (1.0; 5.7)</td>
<td></td>
</tr>
<tr>
<td>Change in total seizure frequency</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reduction</td>
<td>54%</td>
<td>27%</td>
<td>58%</td>
<td>66%</td>
</tr>
<tr>
<td>Difference</td>
<td>43%</td>
<td>28%</td>
<td>42%</td>
<td></td>
</tr>
</tbody>
</table>

Cl = confidence interval; OR = odds ratio

Patients who completed CARE1 and CARE2 (or the phase III studies in Lennox-Gastaut syndrome, CARE3 and CARE4) could receive open-label cannabidiol titrated to 20mg/kg/day in an ongoing safety extension study (CARE5). At an interim analysis, data cut-off 3 November 2016, 75 (28%) of the 264 patients with Dravet syndrome had withdrawn from treatment. Within those remaining on treatment median percent reduction in 28-day convulsive seizure frequency compared with baseline in CARE1 or CARE2 was similar to that in the double-blind studies: 38%, 43%, 43% and 44% after weeks 1 to 12 (n=102), 13 to 24 weeks (n=93), 25 to 36 weeks (n=87) and 37 to 48 weeks (n=75), respectively, in CARE5.²⁵

Summary of evidence on comparative safety

Pooled data from the CARE1 and CARE2 studies showed that adverse events were reported by 88% (195/221) and 82% (108/131) of the ITT population in the cannabidiol and placebo groups (and by 92% (133/144) and 87% (73/84) of the clobazam-treated subgroup). Serious adverse events were reported by 20% and 11% of patients (22% and 11% in the clobazam subgroup), with adverse events leading to discontinuation by 7.2% and 0.8% of patients (6.9% and 1.2% in the clobazam subgroup). Common adverse events within the respective cannabidiol and placebo groups in the ITT population included somnolence or sedation, 28% and 8.4% (40% and 16%); decreased appetite, 24% and 11% (27% and 9.5%); diarrhoea, 22% and 12% (24% and 11%); pyrexia, 20% and 12% (22% and 16%); fatigue, 15% and 8.4% (19% and 8.3%); and vomiting, 12% and 5.3% (12% and 6.0%). The EMA review noted that diarrhoea and decreased appetite were more common in those receiving concomitant sodium valproate. It assessed safety data of CARE1 and CARE2 combined with data from studies CARE3 and CARE4 (in Lennox-Gastaut syndrome), noting that subgroup analyses by disease (Dravet syndrome or Lennox-Gastaut syndrome) did not show any clear difference across the reported adverse events. In these analyses within the cannabidiol and placebo groups rash was reported by 4.2% and 1% of the overall population and pneumonia by 4.8% and 0.7%, respectively. Seizure worsening occurred in 57.54 versus 53.30 cases per 100 patient-years in the cannabidiol and placebo groups, respectively.²

The EMA review noted that hepatotoxicity was the main safety issue. In pooled data from the four phase III studies (CARE1, -2, -3 and -4) within the cannabidiol and placebo groups abnormal liver
adverse events were reported by 15% (68/456) versus 3.1% (9/292), with a higher incidence in the cannabidiol 20mg/kg/day group, compared with the 10mg/kg/day group (18% [54/307] versus 9.4% [13/139]) and a dose-response relationship noted. In the clobazam-treated subgroup these were reported by 20%, 11% and 2.4% of patients in the cannabidiol 20mg/kg/day, 10mg/kg/day and placebo groups, respectively. These were mostly dose-dependent elevations in liver enzymes, primarily transaminases, and the risk was increased in those receiving concomitant sodium valproate and in those with baseline elevated transaminases, with a synergistic increase for patients with both of these risk factors. Concomitant administration of clobazam also increased the risk of elevated transaminases, but to a much lesser extent than sodium valproate. ²

In the pooled studies irritability was reported by 5.5% and 1.7% of patients in the respective groups and aggression by 3.9% and 1.0%. These were reported mainly within the first two weeks for cannabidiol-treated patients, but it was not fully clarified that these were transient. During the studies cognitive tests were performed on a small number of patients and it is not possible to draw any conclusions from this on the effect of cannabidiol on cognitive function or development. Also, the long-term impact of cannabidiol on cognitive and endocrine function is unknown.²

Cannabidiol oral solution contains alcohol that will lead to an alcohol intake above the upper limit of acceptance for children up to six years of age at the 20mg/kg/day dose. The long-term effect of this is unknown.² The summary of product characteristics notes that each mL of cannabidiol oral solution contains 79mg of ethanol. Effects of alcohol in children less than 6 years old may include sleepiness, behavioural changes, and impaired ability to concentrate and participate in school activities. The alcohol content should be taken into account in pregnancy and high-risk groups such as patients with liver disease.¹

### Summary of clinical effectiveness issues

Stiripentol is currently the only other medicine licensed in the EU for treatment of Dravet syndrome. Stiripentol is licensed for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalised tonic-clonic seizures in patients with Dravet’s syndrome whose seizures are not adequately controlled with clobazam and valproate.⁶ SMC has accepted stiripentol for use within NHSScotland in this indication (advice number 524/08). Cannabidiol for the treatment of Dravet syndrome has been designated as an orphan medicine in the EU and it meets SMC criteria for an orphan medicine in this indication.

Dravet syndrome is a severe, lifelong condition characterised by seizures beginning in the first year of life, which can be febrile and afibrile, generalised and unilateral, clonic or tonic–clonic. In addition to convulsive seizures, other seizure types appear between the ages of 1 and 4 years, including myoclonic seizures, focal seizures, and atypical absences. Status epilepticus may occur at initial presentation or later in the clinical course. Patients generally have significant developmental delay apparent from the second year of life onwards, with associated neuropsychological disturbances, and almost all patients have intellectual impairment, which is severe in approximately half of them. Dependency in adulthood is usual and death in childhood is common, for example, due to sudden unexpected death in epilepsy (SUDEP). Many patients with Dravet syndrome (70% to 80%) have abnormalities in the sodium channel α1 subunit gene (SCN1A).²
Stiripentol is the only other medicine specifically licensed for Dravet syndrome, although sodium valproate and clobazam, licensed for use in epilepsy, are widely used in Dravet syndrome. Sodium valproate is often used to prevent initial recurrence of convulsive seizures, and benzodiazepines (for example, diazepam, midazolam, clonazepam, or clobazam) are frequently co-administered to limit the duration of long-lasting seizures. Other treatment options in Dravet syndrome include stiripentol, topiramate, ketogenic diet, levetiracetam, bromides, and vagus nerve stimulation. The National Institute of Health and Care Excellence (NICE) guideline recommends initial treatment of Dravet syndrome with sodium valproate or topiramate and in patients not adequately controlled on first-line therapy clobazam or stiripentol may be added as adjunctive treatment. Polytherapy is common and seizure control is difficult to achieve with current therapies. Clinical experts consulted by SMC note that Dravet syndrome is often refractory to existing AED and there is an unmet need for effective AED to treat this condition.

In the phase III studies (CARE1 and CARE2), cannabidiol compared with placebo significantly reduced the frequency of convulsive seizures, with a percent change relative to baseline of 23% to 30% over placebo. This was driven mainly by effects in the clobazam-treated subgroup, where the difference over placebo was 31% to 43%. The EMA concluded that efficacy in patients who were not receiving clobazam has not been reliably demonstrated and cannabidiol is therefore only licensed for use in combination with clobazam. The EMA considered that its therapeutic effects are produced mainly via an interaction that increases clobazam levels about 3-fold.

The primary outcome was supported by the key secondary outcome, the proportion of patients with at least a 50% reduction in convulsive seizures, and within the clobazam-treated subgroup cannabidiol increased this by 19% to 25% over placebo. There were also benefits with cannabidiol in total seizure frequency reduction and CGIC.

A limitation of the evidence base is that relevant data for the licensed indication are from the clobazam-treated subgroup. This comprised 65% (78/120) and 64% (126/198) of patients in CARE1 and CARE2 respectively. Across both studies within this subgroup only 80 and 45 patients received cannabidiol 20mg/kg/day and 10mg/kg/day respectively. Subgroup data may limit the power of efficacy and safety analyses, but are most likely to represent the benefits and adverse events that may be observed in practice.

Additionally, the change in 28-day convulsive seizure frequency was expressed as a percentage relative to baseline frequency rather than an absolute difference. Upon request the company provided details of the median change from baseline in 28-day convulsive seizure frequency. This was -4.0 and -1.6 in the cannabidiol 20mg/kg/day and placebo groups, respectively in CARE1 and -5.2, -4.7 and -3.8 in the cannabidiol 20mg/kg/day, 10mg/kg/day and placebo groups, respectively in CARE2.

The uptake of cannabidiol can be increased about 4-fold when it is taken with food, compared to the fasted state. The CARE1 and -2 studies did not specify whether cannabidiol should be taken with or without food, which may limit interpretation of efficacy and safety data. Also, the dose titration schedule in these studies (2.5mg/kg/day then increments of 2.5mg/kg/day over 2 days) is different to the licensed schedule (5mg/kg/day then increased after one week to 10mg/kg/day). However, population pharmacokinetic modelling indicated little difference in concentrations between the different titration schedules. Seizure data (type and frequency) were collected by
caregivers in a daily diary, leading to concerns about the quality of data collection due to the limited training of caregivers and potential unblinding of caregivers, who were aware of other clinical information such as dose adjustments, adverse events and changes in the patient’s well-being. However, additional analyses led to a conclusion that the results were robust despite these potential limitations.\(^2\)

The studies do not provide data in children aged less than 2 years or in adults aged more than 18 years. The inclusion criteria specified that patients had epilepsy that was not controlled on current AED.\(^2\) The indication does not specify use in epilepsy inadequately controlled on AED; however, in practice cannabidiol is likely to be used in the patient group.\(^1\) The inclusion criteria specified that patients had at least four convulsive seizures over the 4-week baseline period and there is no evidence in patients who have a seizure frequency lower than this.\(^2\) The studies were not designed to assess effects on psychomotor and cognitive development, which would require longer studies. The open-label extension study is ongoing and currently long-term efficacy data are limited.

The evidence base may not fully characterise rare adverse events or those that occur after long-term administration.\(^2\) The long-term impact of cannabidiol on cognitive and endocrine function and on development of these during childhood is unknown. Cannabidiol oral solution contains alcohol that will lead to an alcohol intake above the upper limit of acceptance for children up to six years of age at the 20mg/kg/day dose. The long-term effects of this are unknown.\(^2\)

Clinical experts consulted by SMC considered that cannabidiol is a therapeutic advancement due to its effects on seizure control in patients with disease that is refractory to other AED. They noted that in practice cannabidiol is likely to be used in addition to a patient’s existing AED therapy, rather than displace another medicine. However, they noted that if cannabidiol improved seizure control it may be possible to reduce other AEDs. They believe that its introduction to practice would not be associated with any substantial service implications.

Patient and clinician engagement (PACE)

A patient and clinician engagement (PACE) meeting with patient group representatives and clinical specialists was held to consider the added value of cannabidiol as an orphan medicine, in the context of treatments currently available in NHSScotland.

The key points expressed by the group were:

- Patients with Dravet syndrome often have frequent, treatment-resistant, severe and debilitating seizures from a young age. Many have developmental delay, learning difficulty, autism, attention-deficit hyperactivity disorder (ADHD) and behavioural difficulties, growth and nutrition problems, infection and immune problems, dysautonomia and issues with sleep, mobility and feeding. They usually require 24-hour care and are fully dependent all their lives. Patients can sustain seizure-related injuries and have an increased risk of death (approximately 15% die before their 18\(^{th}\) birthday) related to seizures or SUDEP. Overall, Dravet syndrome has a devastating and life-long impact on the patient’s quality of life.
Dravet syndrome is an immense strain on the patient’s family. Providing and organising 24-hour care is exhausting for parents. For >90% of families, at least one parent stops work or reduces their hours leading to financial difficulties and stress. The unpredictable and severe nature of seizures and increased risk of death causes parents relentless anxiety with many sleeping in the same room as their child and having poor sleep quality. The severity of the illness creates challenges in obtaining help with the patient’s care and in participation in social activities. Dealing with the disease puts a significant stain on family relationships and >90% of parents develop mental health issues, with many reporting feelings of social isolation.

The disease has a substantial impact on the patient’s siblings. They may be distressed by witnessing seizures and worry about the health of their sibling and parents. They may take on some care responsibilities, have less attention from their parents and have fewer opportunities to participate in social activities.

Most patients take a combination of AEDs, which do not adequately control Dravet syndrome and are associated with side effects. Clinicians estimate that less than 3% of patients have adequate seizure control with currently available AEDs and there is a significant unmet need for new effective therapies that control seizures with an acceptable side effect profile.

A reduction in seizures with cannabidiol positively benefits the patient’s development, improves their comorbidities and ultimately improves their quality of life allowing them to participate more in family life, school and social activities. There are several reports of patients being more alert with cannabidiol and having improved quality of life through resolution of problematic seizure types. Improved seizure control reduces risk of seizure-related injury and death and it is hoped that it may reduce the cumulative impact of seizures on developmental problems associated with this neurological disease.

Improved seizure control lightens the workload of parents caring for a child with Dravet syndrome and reduces their anxiety. It gives the family confidence to participate with more in education, work and social activities and, overall, improves the whole family’s quality of life.

Clinicians noted that clinics have been established to monitor liver function and to assess outcomes. They now have experience in adjusting the doses of AED to manage side effects such as raised liver enzymes. They also note the importance of agreeing with the patient’s carers realistic treatment aims, criteria for monitoring outcomes and an exit strategy. Clinicians also advised that they would aim to discontinue other AED when commencing cannabidiol, especially in the situation where the patient has seizures not adequately controlled by these.
Additional Patient and Carer Involvement
We received patient group submissions from: Dravet Syndrome UK, Epilepsy Action, Epilepsy Connections and Epilepsy Scotland. All four organisations are registered charities. Dravet Syndrome UK has received 11.2% pharmaceutical company funding in the past two years, including from the submitting company. Epilepsy Action has received less than 1% pharmaceutical company funding in the past two years, with none from the submitting company. Epilepsy Connections has not received any pharmaceutical company funding in the past two years. Epilepsy Scotland has received less than 1% pharmaceutical company funding in the past two years, with none from the submitting company. Representatives from all four organisations participated in the PACE meeting. The key points of their submissions have been included in the full PACE statement considered by SMC.

Summary of comparative health economic evidence

The submitting company provided a cost-utility analysis assessing cannabidiol for the treatment of Dravet syndrome, according to the licensed indication. This compared cannabidiol plus clobazam alongside usual care against usual care alone. Usual care was assumed to align with the distribution of treatments observed within the CARE2 clinical trial, with the most frequent treatments represented as clobazam, stiripentol, valproate sodium, valproic acid, levetiracetam and topiramate. SMC clinical experts suggested that sodium valproate, clobazam and stiripentol are the most commonly used medicines within Scotland, but also highlighted that cannabidiol is likely to be used in addition to these therapies. No therapies are expected to be displaced.

A de novo cost-utility analysis was provided in the form of a Markov state-transition cohort model, covering a total of 10 health states. These represented both the number of convulsive seizures per month (‘seizure-free’, ≤8 seizures, >8 - ≤25 and >25), as well as being subdivided into the number of days without convulsive seizures per month (<18, >18 - ≤24 days, >24 days). Patients could transition to an absorbing health state of death at any time. A 3-month cycle length was used and a lifetime (90 year) time horizon applied. A perspective of NHS Scotland and social work was adopted for costs, while outcomes for both patients and two caregivers taken for the original base case. A revised base case, reflecting a ‘patient-only’ perspective, was provided for consistency with SMC processes but the analysis incorporating carer effects was also considered as sensitivity analysis.

Clinical effectiveness data were obtained from the randomised CARE2 study, which informed baseline health state distribution and transitions within the first cycle for both the cannabidiol and usual care cohorts. Patients in the cannabidiol cohort were then modelled to transition between health states up to cycle 9 (27 months), according to data observed in the open-label extension study CARES. No further data were available beyond cycle 1 for the usual care cohort. Following cycle 1 (usual care) and cycle 9 (cannabidiol cohort), patients were assumed to remain in the same health state until death. The only exceptions to this were patients who discontinued cannabidiol treatment, at which point they assumed the health state distribution of the usual care cohort at cycle 1. Discontinuation was based on a proposed stopping rule, where patients who do not achieve a reduction in seizure frequency from baseline of 30% or greater stop treatment at 6
months, 1 year or 2 years. Longer-term treatment discontinuation was based on an assumption of 10% per annum, although a rate of 5% per annum (based on real-world data) was tested in a scenario analysis. Mortality was assumed to remain constant regardless of seizure frequency.

Utility estimates were derived using a direct elicitation exercise, where 8 patients with epilepsy and 20 caregivers of patients with epilepsy were asked to value a series of 23 vignettes through the perspective of a patient with Dravet syndrome using a Visual Analogue Scale. Although not derived using a ‘choice-based’ approach, the company utilised mean estimates from this exercise in the base case (values ranged from 0.75 [‘seizure-free’] to 0.235 (>25 seizures with fewer than 18 seizure-free days]). Caregivers participating in the exercise were asked to value an additional three health states representing a carer of a patient with varying frequencies of epilepsy, resulting in decrements ranging from -0.093 (seizure free) to -0.337 (>25 seizures per month). Estimates of equivalent utilities, where visual analogue scale values were mapped to standard gamble utilities using a published algorithm, were provided in sensitivity analysis.\(^{12}\)

Medicines acquisition costs were included in the evaluation, as well as costs of adverse event management and subsequent treatment of ‘drop-outs’. The dose of cannabidiol was assumed to be constant with the ‘usual’ maintenance dose of 10mg/kg/day in the licensed indication, although the indication allows for patients to receive treatment up to 20mg/kg/day. Scenarios were provided based on assumptions of an average of 11mg/kg/day and 12mg/kg/day, although a further conservative analysis utilising the 20mg/kg/day dose (which more closely aligns with the CARE-5 average dose) was provided upon request. Healthcare resource use was estimated by clinical experts consulted by the company as no data were available; these assumed a general increase in resource requirements such as hospitalisation and paediatric consultations correlating with an increase in seizure frequency.

A Patient Access Scheme (PAS) was submitted by the company and assessed by the Patient Access Scheme Assessment Group (PASAG) as acceptable for implementation in NHSScotland. Under the PAS, a confidential simple discount was offered on the list price. The revised (‘patient-only’ perspective) base case results are shown in Table 3.

**Table 3: Revised base case (patient utility only perspective for benefits)**

<table>
<thead>
<tr>
<th>Technologies</th>
<th>ICER (£/QALY)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Usual-care + placebo</td>
<td>£44,490</td>
</tr>
<tr>
<td>Usual-care + CBD</td>
<td></td>
</tr>
</tbody>
</table>

QALY = quality adjusted life year ICER = incremental cost effectiveness ratio

Disaggregated analyses highlight that the costs of treatment acquisition are the predominant incremental costs, while management costs per patient represent the largest cost offset. Similarly, the majority of QALY gains are achieved by increased proportions of cannabidiol patients entering the ‘seizure-free’ health state.

Key scenario analyses, including the original base case incorporating the carer perspective, are shown below. These highlight particular upwards sensitivity to the dose of cannabidiol and
treatment duration (via discontinuation rates and stopping rule), the approach to estimating utilities and more conservative approaches to modelling caregiver disutility.

Table 4: Key scenario analyses

<table>
<thead>
<tr>
<th>Scenario number</th>
<th>Parameter</th>
<th>Revised base case</th>
<th>Scenario analyses</th>
<th>ICER</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>‘Patient only’ base case</td>
<td>N/A</td>
<td>N/A</td>
<td>£44,490</td>
</tr>
<tr>
<td>1.</td>
<td>CBD dosage</td>
<td>All patients receiving 10 mg/kg/day</td>
<td>Average dose: 12 mg/kg/day</td>
<td>£59,938</td>
</tr>
<tr>
<td>2.</td>
<td></td>
<td></td>
<td>Average dose: 20 mg/kg/day</td>
<td>£123,349</td>
</tr>
<tr>
<td>3.</td>
<td></td>
<td>Calculated based on median weight from trials</td>
<td>Calculated based on mean weight</td>
<td>£48,302</td>
</tr>
<tr>
<td>4.</td>
<td>Utilities</td>
<td>VAS estimates provided by patients/caregivers</td>
<td>Mapping algorithms to Standard Gamble (highest and lowest estimates)</td>
<td>£45,461 - £67,136</td>
</tr>
<tr>
<td>5.</td>
<td>Ratio ICU/General ward for hospitalised seizures</td>
<td>5% in ICU and 95% in general ward</td>
<td>50% in ICU and 50% in general ward</td>
<td>£31,624</td>
</tr>
<tr>
<td>6.</td>
<td>Stopping rules</td>
<td>First time-point at 6 months</td>
<td>No stopping rules</td>
<td>£57,941</td>
</tr>
<tr>
<td>7.</td>
<td>Discontinuation rates</td>
<td>Assume 10% per annum after cycle 1</td>
<td>Real-world data (5% per annum) after cycle 1</td>
<td>£52,557</td>
</tr>
<tr>
<td>8.</td>
<td>Caregiver disutility</td>
<td>Patient utilities only</td>
<td>Consideration of disutility for primary caregiver</td>
<td>£30,161</td>
</tr>
<tr>
<td>9.</td>
<td>Caregiver disutility</td>
<td>Equal disutilities for two caregivers (company base case)</td>
<td></td>
<td>£22,813</td>
</tr>
<tr>
<td>10.</td>
<td>Combined scenario (utility of 1 caregiver)</td>
<td>See base case</td>
<td>Scenarios 1, 4, 8 plus: - Equal hospitalisation rates and consultant visits regardless of seizure frequency</td>
<td>£61,458</td>
</tr>
<tr>
<td>11.</td>
<td>Combined scenario (utility of 1.5 caregivers)</td>
<td>As Scenario 10, with disutility of primary caregiver multiplied by 1.5</td>
<td></td>
<td>£53,400</td>
</tr>
</tbody>
</table>
Following the New Drugs Committee (NDC) consideration of the submission, the company conducted a further study to assess health related quality of life. This aimed to address some of the concerns raised by NDC about the methods used. For the revised utility study, patient vignettes were iteratively reviewed by two LGS and DS expert clinicians and the carer vignettes were constructed from the perspective of someone who is one of two primary caregivers/parents of a 10-year old child. The vignettes were then valued using the time-trade off methodology in members of the general public in the UK (n=150) and Sweden (n=50).

Key results using this revised approach are presented in table 5. These figures were considered relevant for decision-making by SMC as the approach to estimating utilities was considered an improvement on the base case approach by employing preference-based methods and resolving some concerns regarding multiplicative estimation of carer burden.

Table 5: Key results using revised utility study

<table>
<thead>
<tr>
<th>Analysis</th>
<th>ICER with PAS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Base case using patient only perspective on benefits</td>
<td>£42,999</td>
</tr>
<tr>
<td>Base case using patient and carer perspective on health benefits (company base case)</td>
<td>£18,528</td>
</tr>
<tr>
<td>Combined scenario (as per scenario 10, table 4)</td>
<td>£50,142</td>
</tr>
</tbody>
</table>

The following limitations are noted regarding the economic evaluation:

- The approach to valuing caregiver disutility as originally presented in the submission was associated with uncertainty. The valuation study required participants to consider the impact on a single carer, without discussing involvement of a partner or second carer. Despite this, a simple multiplication of utility for two carers was applied, which may overestimate the extent of disutility. An estimate of caregiver disutility for 1 carer was obtained and falls between the original and revised base case (Table 4, scenarios 8 and 9). The revised analysis presented in table 5 helped to address the concerns in the originally submitted analysis. This revised analysis also used preference-based measures and thus addressed the concerns of NDC that the original approach to patient utilities did not use a choice-based method.

- The expected average dose of cannabidiol is unknown, as the licensed indication allows dose escalation to 20mg/kg/day whereas the randomized trial data did not. The submitting company assumed an average of up to 12mg/kg/day will be used in practice, based on a recent observational study only published in abstract form. However, an Expanded Access Programme for cannabidiol reported an average dose higher than the maximum licensed dose; therefore the average dose could plausibly increase further towards 20mg/kg/day. Increases in dose above 10mg/kg/day result in a significant upwards effect on the ICER (scenario 1 and 2). Median weight was used to estimate total cannabidiol dose, rather than mean. Use of mean weights is more appropriate and results in a moderate increase in the ICER (Table 4, scenario 3).

- No long-term data are available beyond 27 months, yet the treatment benefit is assumed to be
maintained for the remainder of 90 years. The submitting company was unable to provide alternative estimates where treatment waning was assumed, although provided a separate scenario where patients were assumed to remain on treatment for three months following loss of efficacy. This had limited effect on the ICER (not shown), although the ICER effect of patients receiving lower long-term benefit whilst remaining on treatment remains unknown.

A range of combined scenarios were obtained, which test some of the key uncertainties (Table 4, scenarios 10 and 11, table 5 combined scenario). It should be noted that the ICER could plausibly increase beyond this point, as amendments influencing the cost of cannabidiol acquisition (such as the use of mean rather than median dose and a discontinuation rate observed in practice) have not been included. However, the submitting company did also use some conservative approaches, for example the impact of sudden unexpected death due to epilepsy was not included in the analysis and assuming a low proportion of patients requiring intensive care upon hospitalisation (Table 4 scenario 5), which could have a positive impact on the cost-effectiveness of cannabidiol. The submitting company also asserted that there were a range of other benefits that were not easily captured in the economic model; wider quality of life impacts on wider members such as siblings; reducing the number of non-convulsive seizures and reductions in the duration and severity of seizures; potential reductions in concomitant medications; and potential longer term impacts of improved seizure control on cognitive function, behaviour and injury.

The Committee considered the benefits of cannabidiol in the context of SMC decision modifiers that can be applied when encountering high cost-effectiveness ratios and agreed that as cannabidiol is an orphan medicine, SMC can accept greater uncertainty in the economic case.

After considering all the available evidence, the output from the PACE process and after application of the appropriate SMC modifiers, the Committee accepted cannabidiol for use in NHSScotland.

*Other data were also assessed but remain confidential.*

**Additional information: guidelines and protocols**

The National Institute of Health and Clinical Excellence (NICE) published in January 2012 and last updated in October 2019 clinical guideline 137, epilepsies: diagnosis and management. This recommends discussion with or referral to a tertiary paediatric epilepsy specialist when a child presents with suspected Dravet syndrome. Consider sodium valproate or topiramate as first-line treatment in children with Dravet syndrome. Follow the MHRA safety advice on sodium valproate. It also recommends discussion with a tertiary epilepsy specialist if first-line treatments in children, young people and adults with Dravet syndrome are ineffective or not tolerated, and consider clobazam or stiripentol as adjunctive treatment. Do not offer carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, pregabalin, tiagabine or vigabatrin.11
The Scottish Intercollegiate Guidelines Network (SIGN) issued publication number 148: diagnosis and management of epilepsy in adults in May 2015 and it was updated in 2018. This makes no specific recommendations on the treatment of Dravet syndrome.\textsuperscript{15}

**Additional information: comparators**

It is expected that cannabidiol will be used in addition to existing AED.

**Additional information: list price of medicine under review**

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Dose Regimen</th>
<th>Cost per year (£)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cannabidiol</td>
<td>5mg to 10mg/kg/day orally twice daily</td>
<td>3,714 to 37,141</td>
</tr>
</tbody>
</table>

*Costs from SMC New Product Assessment Form (NPAF) based on a body weight ranging from 12kg to 60kg. Costs do not take any patient access schemes into consideration.*

**Additional information: budget impact**

SMC is unable to publish the with PAS budget impact due to commercial in confidence issues. A budget impact template is provided in confidence to NHS health boards to enable them to estimate the predicted budget with the PAS.

*Other data were also assessed but remain confidential.*
References
1. GW Pharma Ltd. Cannabidiol 100mg/mL oral solution (Epidyolex®) summary of product characteristics. Electronic Medicines Compendium www.medicines.org.uk/emc/. Last updated 4.11.19
10. UCB Pharma Ltd. Levetiracetam 100mg/mL oral solution (Keppra®) summary of product characteristics. Electronic Medicines Compendium www.medicines.org.uk/emc/. Last updated 30.10.19.
13. Chemaly N, Villeneuve N, De Saint Martin et al. TOLÉRANCE ET EFFICACITÉ DU CANNABIDIOL EN OUVERT (ATU) DANS UNE COHORTE DE PATIENTS SUIVIS AU CENTRE DE RÉFÉRENCE DES ÉPILEPSIES RARES. Congrès de la Société Française de Neurologie Pédiatriq 2020

This assessment is based on data submitted by the applicant company up to and including 4 March 2020.
*Agreement between the Association of the British Pharmaceutical Industry (ABPI) and the SMC on guidelines for the release of company data into the public domain during a health technology appraisal: http://www.scottishmedicines.org.uk/About_SMC/Policy*

Medicine prices are those available at the time the papers were issued to SMC for consideration. SMC is aware that for some hospital-only products national or local contracts may be in place for comparator products that can significantly reduce the acquisition cost to Health Boards. These contract prices are commercial in confidence and cannot be put in the public domain, including via the SMC Detailed Advice Document. Area Drug and Therapeutics Committees and NHS Boards are therefore asked to consider contract pricing when reviewing advice on medicines accepted by SMC.

Patient access schemes: A patient access scheme is a scheme proposed by a pharmaceutical company in order to improve the cost-effectiveness of a medicine and enable patients to receive access to cost-effective innovative medicines. A Patient Access Scheme Assessment Group (PASAG), established under the auspices of NHS National Services Scotland reviews and advises NHSScotland on the feasibility of proposed schemes for implementation. The PASAG operates separately from SMC in order to maintain the integrity and independence of the assessment process of the SMC. When SMC accepts a medicine for use in NHSScotland on the basis of a patient access scheme that has been considered feasible by PASAG, a set of guidance notes on the operation of the scheme will be circulated to Area Drug and Therapeutics Committees and NHS Boards prior to publication of SMC advice.

**Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after careful consideration and evaluation of the available evidence. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*